Everstar Therapeutics Limited Report issue

For profit Phase 1 Phase 3
Founded: Hong Kong China (2018)

Organization Overview

First Clinical Trial
2019
NCT04176588
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Everstar Medicines (Shanghai) Limited | Everstar Therapeutics Limited

Active Ingredients

Drugs in Phase 3 Trials (1)

etrasimod (Velsipity) (1 trial)

Drugs in Phase 1 Trials (1)

ralinepag (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2